

Correction

MEDICAL SCIENCES

Correction for “Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors,” by Charles Li, Elena Bonazzoli, Stefania Bellone, Jungmin Choi, Weilai Dong, Gulden Menderes, Gary Altwerger, Chanhee Han, Aranzazu Manzano, Anna Bianchi, Francesca Pettinella, Paola Manara, Salvatore Lopez, Ghanshyam Yadav, Francesco Riccio, Luca Zammataro, Burak Zeybek, Yang Yang-Hartwich, Natalia Buza, Pei Hui, Serena Wong, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Valentina Zizioli, Franco Odicino, Sergio Pecorelli, Laura Ardighieri, Dan-Arin Silasi, Babak Litkouhi, Elena Ratner, Masoud Azodi, Gloria S. Huang, Peter E. Schwartz, Richard P. Lifton, Joseph Schlesinger, and Alessandro D. Santin, which was first published December 24, 2018; 10.1073/pnas.1814027116 (*Proc Natl Acad Sci USA* 116:619–624).

The authors note that the following statement should be added to the Acknowledgments: “This work was also supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program under Award W81XWH-15-1-0221 (to Y.Y.-H).”

Published under the [PNAS license](#).

Published online March 11, 2019.

www.pnas.org/cgi/doi/10.1073/pnas.1902633116